NIH Platelets Grant opportunity - closes 2/20/2015
Feb 12, 2015 20:24:56 GMT
CM kipper007 and jckrdu like this
Post by actcfan on Feb 12, 2015 20:24:56 GMT
I guess this would not qualify as "Partnership of non-core asset" - but sure seems like the kind of thing OCAT should be applying for (assuming there are no CIRM type strings attached). Looks like it closes 2/20/2015 and is reviewed in June. Not a lot of money but better than Platelets just being shelved.. Long shot but thought i would share it anyway.
grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-022.html
RFA-HL-15-022
Stem Cell-Derived Blood Products for Therapeutic Use (R01)
Department of Health and Human Services
National Institutes of Health
Estimated Total Program Funding: $3,600,000
Award Ceiling: $300,000
Agency Name: National Institutes of Health
Description: Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells. In addition to this FOA, two companion FOAs (RFA-HL-15-029 and RFA-HL-15-030) will support small business research to develop improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner.
grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-022.html
RFA-HL-15-022
Stem Cell-Derived Blood Products for Therapeutic Use (R01)
Department of Health and Human Services
National Institutes of Health
Estimated Total Program Funding: $3,600,000
Award Ceiling: $300,000
Agency Name: National Institutes of Health
Description: Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells. In addition to this FOA, two companion FOAs (RFA-HL-15-029 and RFA-HL-15-030) will support small business research to develop improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner.
